GLP-1 Receptor Agonist Market Report Snapshot Market Segmentation By Molecule (Liraglutide, Dulaglutide, Semaglutide, Tirzepatide, and Others): The tirzepatide segment earned USD 27.14 billion in 2025, primarily due to superior efficacy in both glycemic control and weight reduction, rapid uptake among healthcare providers, and expanded diabetes and obesity indications, positioning it as a preferred GLP-1 therapy option
Lilly sells the GLP-1/GIP drug tirzepatide as Mounjaro and Zepbound
Mulberry leaf extract improves glycaemic response and insulaemic response to sucrose in healthy subjects: results of a randomized, double blind, placebo-controlled study
Indoor cycling is great for the 150 minutes moderate-intensity activity. Indoor cycling during or after GLP-1 treatment The exercise prescription for GLP-1 patients is the same as for the general adult population: 150 minutes of at least moderate-intensity activities each week, plus at least two strength training sessions a week
Medical professionals and insurance benefits administrators have started avidly searching for effective off-ramps for people on GLP-1s
